EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A neuraminidase-targeting nanobody as a therapeutic candidate against influenza A and B viruses

Donglan Liu iD, Yuxuan Zhang, Min Zhang iD, Raoqing Guo, Wanwan Peng, Ren Cao, Xiaoyun Yang, Jiayan Chen, Si Huang, Jinwei Li, Chen Sheng, Liuxing Qin iD

Journal of Virology · 2026

DOI: 10.1128/jvi.00874-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2026. Verfasst von Donglan Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, th…. Hauptthemen laut MEDLINE: Neuraminidase, Single-Domain Antibodies, Influenza A virus, Antiviral Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prevention and Control of Emerging and Major Infection Diseases-National Science and Techology Major Project, Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project, Major Project of Guangzhou National Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza viruses continue to pose a significant threat to human and animal health. However, the limited number of licensed antivirals is increasingly compromised by drug resistance driven by high mutation rates. This highlights the urgent need for broad-spectrum therapeutics with novel mechanisms of action. Nanobodies, a new generation of antibody drugs, have great potential in the treatment of influenza virus infections. Neuraminidase (NA) mediates the sialic acid cleavage required for viral release, and its genetic drift is generally slower than that of hemagglutinin (HA) in influenza viruses, making it an attractive target for broad-spectrum antiviral and vaccine development. To construct a phage display nanobody library targeting NA, an alpaca was immunized with the NA protein of the H9N2 influenza virus. A specific nanobody, designated F4, was subsequently screened from the immune library. The nanobody was engineered into an Fc-fused nanobody, F4-Fc, which exhibited inhibitory activity against multiple influenza A and B viruses in vitro and provided robust prophylactic and therapeutic protection against influenza A and influenza B virus infections in vivo . Mechanistically, F4-Fc inhibits NA enzymatic activity and mediates antibody-dependent cellular cytotoxicity. In conclusion, F4-Fc demonstrates prophylactic and therapeutic efficacy against influenza A and B viruses, representing a promising antiviral drug candidate for influenza virus infection. IMPORTANCE Influenza viruses seriously threaten human and animal health, and drugs are crucial for controlling influenza outbreaks. However, the limited variety of existing anti-influenza virus medicines and the high mutation rate of the virus have led to the continuous emergence of drug-resistant strains. Neuraminidase (NA) is a critical surface glycoprotein that exhibits slower antigenic drift than hemagglutinin (HA), making it an attractive target for cross-protective antiviral development. However, broadly active NA-targeting nanobodies, particularly those effective against both influenza A and B viruses, remain limited. Here, we constructed an Fc-fused F4 nanobody (F4-Fc) targeting neuraminidases from multiple influenza A and B viruses and demonstrated its antiviral efficacy in vitro and protective activity in vivo , highlighting its potential as a promising strategy for the prevention and treatment of influenza virus infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuraminidaseSingle-Domain AntibodiesInfluenza A virusAntiviral AgentsOrthomyxoviridae InfectionsInfluenza B virusViral ProteinsAnimalsHumansAntibodies, ViralCamelids, New WorldDogsInfluenza A Virus, H9N2 SubtypeMice

Stichwörter der Autor:innen

antiviral mechanismsimmunotherapyinfluenza virusnanobodyneuraminidase

Substanzen

NeuraminidaseSingle-Domain AntibodiesAntibodies, ViralAntiviral AgentsViral Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou…
  • Guangzhou National Laboratory, Bio-island, Guangzhou, China.
  • Guangzhou Medical University, Guangzhou, China.
  • School of Chemistry and Chemical Engineering, University of South China, Hengyang, China.

ORCID-Profile: Donglan Liu, Min Zhang, Liuxing Qin

Förderung

  • Prevention and Control of Emerging and Major Infection Diseases-National Science and Techology Major Project
  • Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project
  • Major Project of Guangzhou National Laboratory
  • Postdoctoral Scientific Research Start-up Found of Guangzhou
  • Guangdong High-Level Talent Program
  • National Natural Science Foundation of China

Zitieren

APA

Liu, D., Zhang, Y., Zhang, M., Guo, R., Peng, W., Cao, R., Yang, X., Chen, J., Huang, S., Li, J., Sheng, C., & Qin, L. (2026). A neuraminidase-targeting nanobody as a therapeutic candidate against influenza A and B viruses. Journal of Virology. https://doi.org/10.1128/jvi.00874-26

Vancouver

Liu D, Zhang Y, Zhang M, Guo R, Peng W, Cao R, et al. A neuraminidase-targeting nanobody as a therapeutic candidate against influenza A and B viruses. Journal of Virology. 2026. doi:10.1128/jvi.00874-26

BibTeX
@article{Liu2026,
  author = {Liu, Donglan and Zhang, Yuxuan and Zhang, Min and Guo, Raoqing and Peng, Wanwan and Cao, Ren and Yang, Xiaoyun and Chen, Jiayan and Huang, Si and Li, Jinwei and Sheng, Chen and Qin, Liuxing},
  title = {A neuraminidase-targeting nanobody as a therapeutic candidate against influenza A and B viruses},
  journal = {Journal of Virology},
  year = {2026},
  doi = {10.1128/jvi.00874-26}
}
Kostenlos starten →